Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02957682 · ClinicalTrials.gov registry record · Phase 4

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

A Phase 4 study of Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
2,176
Enrollment target
20
Study locations

NCT02957682 is a Phase 4 study of Hypercholesterolemia that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 2,176 participants, above the 782-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (178% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02957682, a Phase 4 study of Hypercholesterolemia, has completed, sponsored by Regeneron Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
2,176 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.

Conditions Studied

Hypercholesterolemia

Interventions

  • DRUG Placebo
  • DRUG Praluent (Alirocumab)

Study Locations (20)

California

  • Regeneron Study Site - Beverly Hills
  • Regeneron Study Site - Los Gatos
  • Regeneron Study Site - North Hollywood
  • Regeneron Study Site - Port Hueneme
  • Regeneron Study Site - Westminster

Illinois

  • Regeneron Study Site - Champaign
  • Regeneron Study Site - Chicago
  • Regeneron Study Site - Chicago
  • Regeneron Study Site - Rock Island

Alabama

  • Regeneron Study Site - Auburn
  • Regeneron Study Site - Birmingham
  • Regeneron Study Site - Mobile

Colorado

  • Regeneron Study Site 1 - Aurora
  • Regeneron Study Site 2 - Aurora
  • Regeneron Study Site - Colorado Springs

Florida

  • Regeneron Study Site - Lake Worth
  • Regeneron Study Site - Lake Worth
  • Regeneron Study Site - Miami Springs

Georgia

  • Regeneron Study Site - Covington

Indiana

  • Regeneron Study Site - Evansville

Trial Details

FieldValue
Enrollment Target 2,176 participants
Start Date 2016-11-02
Est. Completion 2020-03-05
Phase Phase 4

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02957682

The ClinicalTrials.gov registry entry for NCT02957682 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,176 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 782-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (178% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02957682 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, Alabama.

Frequently Asked Questions

What is clinical trial NCT02957682 about?

NCT02957682 is a clinical study titled "Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo". The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.

What is the current status of trial NCT02957682?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,176 participants. The study started on 2016-11-02. Estimated completion is 2020-03-05.

What conditions does trial NCT02957682 study?

This clinical trial studies the following conditions: Hypercholesterolemia.

What interventions are being tested in trial NCT02957682?

The interventions under investigation include: Placebo (DRUG), Praluent (Alirocumab) (DRUG).

Who is sponsoring clinical trial NCT02957682?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02957682 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypercholesterolemia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.